Over the past few years, a class of compounds known as GLP receptor agonists has gone from niche academic interest to one of the most discussed topics in metabolic science. Most people will have heard of semaglutide — sold commercially as Ozempic and Wegovy — but the broader science behind how these compounds work, and where research is heading, is worth understanding properly.
What Is the GLP-1 Receptor?
GLP-1 stands for glucagon-like peptide-1. It is a hormone produced naturally in the gut, primarily in response to eating. Its role is to signal to the pancreas to release insulin, slow the rate at which the stomach empties, and communicate to the brain that the body has received food.
The GLP-1 receptor is the molecular target these compounds bind to. When a GLP-1 receptor agonist activates this receptor, it essentially amplifies the signals the body already produces naturally — encouraging the pancreas to respond to blood glucose, reducing appetite, and slowing digestion.
This mechanism is why GLP-1 research began in the context of type 2 diabetes. The ability to improve insulin response without causing hypoglycaemia was a significant development in diabetes management research.
Beyond GLP-1: The Dual and Triple Agonist Research Frontier
More recent research has moved beyond targeting GLP-1 in isolation. Scientists began investigating what happens when you combine GLP-1 receptor activation with other metabolic receptors — specifically GIP (glucose-dependent insulinotropic polypeptide) and glucagon.
GIP is another gut hormone that enhances insulin secretion and plays a role in how the body handles fat. For years it was considered a problematic target because some early research suggested GIP might oppose weight loss. More recent work has complicated this picture significantly, and current thinking is that combined GLP-1 and GIP activation may produce greater metabolic effects than either alone.
Glucagon is perhaps the more surprising addition. It is primarily known for its role in raising blood glucose — broadly the opposite of insulin. However, glucagon receptor activation in the context of combined agonism appears to increase energy expenditure and support fat mobilisation, adding a thermogenic dimension to the metabolic picture.
Tirzepatide, which targets both GLP-1 and GIP receptors, was the first dual agonist to reach widespread clinical use. Trial data published in the New England Journal of Medicine showed weight reductions of approximately 20–21% over 72 weeks, significantly outperforming earlier GLP-1-only compounds.
Where Current Research Stands: Triple Agonists
The next stage of investigation involves compounds that activate all three receptors simultaneously. Several are currently in clinical trials, with retatrutide among the most closely watched.
Phase 2 trial data published in the New England Journal of Medicine in 2023 reported that all participants receiving the highest doses experienced meaningful weight loss, with reductions of up to 24% of body weight over 48 weeks — results that have attracted significant scientific attention.
It is important to note that phase 2 trials are not the final word. They establish proof of concept, explore dosing, and identify side effects — but they involve smaller cohorts and shorter timeframes than the phase 3 trials required before any compound can be considered for regulatory approval. All compounds in this space remain under active investigation.
The most commonly reported side effects across this class are gastrointestinal — nausea, vomiting, and diarrhoea — which tend to be most pronounced when doses are escalated too quickly. Clinical protocols typically begin at low doses and increase gradually over several weeks.
The Science of Appetite Regulation
One of the more interesting aspects of GLP receptor research is what it has revealed about how appetite is regulated at a biological level.
For decades, the prevailing assumption in nutrition and weight management was that eating less was primarily a matter of willpower. The emerging science paints a more complex picture. The brain receives continuous chemical signals from the gut, the pancreas, and fat tissue — and these signals directly influence hunger, satiety, and how much energy the body expends at rest.
GLP-1 receptor activation appears to work on the hypothalamus and brainstem — regions involved in hunger and satiety signalling. Research has also suggested effects on the reward pathways associated with food, which may explain why some trial participants report reduced cravings for highly palatable foods, not just reduced hunger overall.
These mechanisms are not yet fully understood, and scientists are still working to establish which aspects of GLP receptor activation are responsible for which effects.
Metabolic Research: A Broader Picture
The potential applications being studied extend well beyond weight management. Researchers are investigating GLP receptor agonism in the context of:
Non-alcoholic fatty liver disease: Preliminary research suggests these compounds may reduce liver fat accumulation and inflammation, significant given that fatty liver disease is closely linked to insulin resistance and metabolic syndrome.
Cardiovascular outcomes: Several large trials have shown that GLP-1 receptor agonists reduce the risk of major cardiovascular events in people with type 2 diabetes. The mechanisms remain under investigation.
Kidney disease: Some research has suggested protective effects on kidney function in people with diabetes, though this remains an emerging area.
Neurological research: There is growing interest in GLP-1 signalling in the brain beyond appetite regulation, including early-stage research into neurodegenerative conditions. This is preliminary and should be treated cautiously.
A Note on Research vs Clinical Use
It is worth being clear about where the science currently sits. Semaglutide and tirzepatide are licensed medicines, available on prescription, with regulatory approval in specific indications. Everything else discussed in this article — including triple agonists and newer compounds in this class — remains in clinical trials or earlier stages of research.
Research-grade peptides used in scientific investigation are a separate category from licensed medicines. They are used in controlled laboratory and clinical settings to advance understanding of how these mechanisms work.
If you are interested in GLP-1-related medications for personal health reasons, that conversation belongs with your GP or a specialist. The science is genuinely exciting, but it is still science — and the gap between a promising phase 2 trial result and a safe, approved medicine involves years of additional work.
Why This Research Matters
The scale of metabolic disease globally — obesity, type 2 diabetes, cardiovascular disease, fatty liver — represents one of the most significant public health challenges of the current era. GLP receptor research sits at the intersection of several of these conditions, which is part of why it has attracted such intense scientific interest.
Understanding how the body regulates appetite, blood glucose, energy expenditure, and fat storage at a molecular level is genuinely valuable — not just for developing treatments, but for understanding what is happening when these systems go wrong. The science is moving quickly, and the GLP receptor story is far from finished.
Further Reading
For those who want to explore the clinical trial data directly:
- Jastreboff et al. (2023), Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist for Obesity — New England Journal of Medicine
- Frías et al. (2021), Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — New England Journal of Medicine
- Wilding et al. (2021), Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine
The information in this article is provided for general educational and informational purposes only. It is not intended as medical advice and should not be treated as such. Always consult a qualified medical professional before making decisions about your health.
